当前位置:
X-MOL 学术
›
Int. J. Impot. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease.
International Journal of Impotence Research ( IF 2.6 ) Pub Date : 2019-02-11 , DOI: 10.1038/s41443-019-0127-x Thomas Masterson 1 , Premal Patel 1 , Ranjith Ramasamy 1
International Journal of Impotence Research ( IF 2.6 ) Pub Date : 2019-02-11 , DOI: 10.1038/s41443-019-0127-x Thomas Masterson 1 , Premal Patel 1 , Ranjith Ramasamy 1
Affiliation
Comment
中文翻译:
回复:在获得FDA批准用于治疗Peyronie病后,溶组织梭状芽孢杆菌胶原酶的成功有限。
评论
更新日期:2019-07-05
中文翻译:
回复:在获得FDA批准用于治疗Peyronie病后,溶组织梭状芽孢杆菌胶原酶的成功有限。
评论